NFDI4DS | UHH-SEMS - Publication Details

Benjamin J. Bulen

ORCID: 0009-0002-4070-665X

Publications

Citations

Views

---

Saved

---

About

Contact & Profiles

A5010766249

Research Areas

Cancer Immunotherapy and Biomarkers
Radiomics and Machine Learning in Medical Imaging
Colorectal and Anal Carcinomas
Inflammatory Biomarkers in Disease Prognosis
Esophageal Cancer Research and Treatment
Multiple and Secondary Primary Cancers
Lung Cancer Research Studies
Bladder and Urothelial Cancer Treatments
Cancer Genomics and Diagnostics
Pancreatic and Hepatic Oncology Research
Colorectal Cancer Treatments and Studies
Immune Cell Function and Interaction
Lymphoma Diagnosis and Treatment
Lung Cancer Treatments and Mutations
Ferroptosis and cancer prognosis
Genetic factors in colorectal cancer
Health Systems, Economic Evaluations, Quality of Life
Immunotherapy and Immune Responses
PARP inhibition in cancer therapy
Microscopic Colitis

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

OPENALEX - Publications

Scott A. Tomlins Nickolay A. Khazanov Benjamin J. Bulen Daniel H. Hovelson Melissa J. Shreve and 37 more

Abstract Background Anti-PD-1 and PD-L1 (collectively PD-[L]1) therapies are approved for many advanced solid tumors. Biomarkers beyond immunohistochemistry, microsatellite instability, tumor mutation burden (TMB) may improve benefit prediction. Methods Using treatment data genomic transcriptomic tissue profiling from an observational trial (NCT03061305), we developed Immunotherapy Response Score (IRS), a pan-tumor predictive model of PD-(L)1 benefit. IRS real-world progression free survival...

10.1038/s43856-023-00243-7 article EN cc-by Communications Medicine 2023-02-07

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Immunotherapy response score (IRS) integrates tumor mutation burden (TMB) and quantitative expression biomarkers to predict anti-PD-1/PD-L1 [PD-(L)1] monotherapy benefit. Here, we evaluated IRS in additional cohorts. Patients from an observational trial (NCT03061305) treated with anti-PD-(L)1 were included assigned IRS-High (-H) versus -Low (-L) groups. Associations real-world progression-free survival (rwPFS) overall (OS) determined by Cox proportional hazards (CPH) modeling. Those...

10.1158/2767-9764.crc-23-0036 article EN cc-by Cancer Research Communications 2023-07-03

PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)

OPENALEX - Publications

Brandi Oakley Justin S. Moon M. Kari Connolly Mark E. Burkard Jennifer M. Suga and 13 more

10.1016/j.jtho.2024.05.333 article EN Journal of Thoracic Oncology 2024-07-01

Supplementary Figure S8 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Figure S8. shows overlap weighting propensity score analysis of the chemotherapy, anti-PD-(L)1, and chemotherapy + anti-PD-(L)1 validation cohort

10.1158/2767-9764.23618593.v1 preprint EN cc-by 2023-07-03

Supplementary Data S1 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Data S1 shows the REMARK checklist for study

10.1158/2767-9764.23618620 preprint EN cc-by 2023-07-03

Supplementary Figure S5 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Figure S5 shows robustness of Immunotherapy Response Score to self-reported race

10.1158/2767-9764.23618602 preprint EN cc-by 2023-07-03

Supplementary Figure S7 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Figure S7. shows covariate adjusted Kaplan-Meier analysis of the chemotherapy, anti-PD-(L)1, and chemotherapy + anti-PD-(L)1 validation cohort

10.1158/2767-9764.23618596.v1 preprint EN cc-by 2023-07-03

Supplementary Figure S2 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Figure S2 shows a diagram of the overall study

10.1158/2767-9764.23618611 preprint EN cc-by 2023-07-03

Supplementary Figure S6 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Figure S6 shows three group Immunotherapy Response Score classification of the anti-PD-(L)1 monotherapy validation cohort

10.1158/2767-9764.23618599.v1 preprint EN cc-by 2023-07-03

Supplementary Figure S7 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Figure S7. shows covariate adjusted Kaplan-Meier analysis of the chemotherapy, anti-PD-(L)1, and chemotherapy + anti-PD-(L)1 validation cohort

10.1158/2767-9764.23618596 preprint EN cc-by 2023-07-03

Supplementary Figure S8 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Figure S8. shows overlap weighting propensity score analysis of the chemotherapy, anti-PD-(L)1, and chemotherapy + anti-PD-(L)1 validation cohort

10.1158/2767-9764.23618593 preprint EN cc-by 2023-07-03

Supplementary Data S1 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Data S1 shows the REMARK checklist for study

10.1158/2767-9764.23618620.v1 preprint EN cc-by 2023-07-03

Supplementary Figure S1 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

OPENALEX - Publications

Benjamin J. Bulen Nickolay A. Khazanov Daniel H. Hovelson Laura E. Lamb Marc Matrana and 33 more

Supplementary Figure S1 shows analytical validation of the gene expression component Immunotherapy Response Score components vs. qRT-PCR

10.1158/2767-9764.23618614 preprint EN cc-by 2023-07-03

Coming Soon ...